Skip to main content

Rapport Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 10, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 10, 2026

RAPP$26.07+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 16. Form 10-K Summary

None.

SIGN ATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Rapport Therapeutics, Inc.
Date: March 10, 2026By:/s/ Abraham N. Ceesay
Abraham N. Ceesay, M.B.A.
Chief Executive Officer and Director

POWER OF ATTORNEY AND SIGNATURES

KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Abraham N. Ceesay, M.B.A. and Troy Ignelzi, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Annual Report on Form 10-K has been signed by the following person in the capacities and on the date indicated.

SignatureTitleDate
/s/ Abraham N. CeesayChief Executive Officer and DirectorMarch 10, 2026
Abraham N. Ceesay, M.B.A.(Principal Executive Officer)
/s/ Troy IgnelziChief Financial OfficerMarch 10, 2026
Troy Ignelzi(Principal Financial Officer and Principal Accounting Officer)
/s/ Steven M. PaulDirector and ChairmanMarch 10, 2026
Steven M. Paul, M.D.
/s/ James I. HealyDirectorMarch 10, 2026
James I. Healy, M.D., Ph.D.
/s/ John MaraganoreDirectorMarch 10, 2026
John Maraganore, Ph.D.
/s/ Paul SilvaDirectorMarch 10, 2026
Paul Silva
/s/ Raymond SanchezDirectorMarch 10, 2026
Raymond Sanchez, M.D.
/s/ Robert J. PerezDirectorMarch 10, 2026
Robert J. Perez
/s/ Reid HuberDirectorMarch 10, 2026
Reid Huber, Ph.D.
/s/ Wendy B. YoungDirectorMarch 10, 2026
Wendy B. Young, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.